Breast fine-needle aspiration malondialdehyde deoxyguanosine adduct in breast cancer.

This study has analysed the generation of 3-(2-deoxy-ββ-D-erythro-pentafuranosyl)pyrimido[1,2-αα]purin-10(3H)-one deoxyguanosine adduct [M₁dG], a biomarker of oxidative stress and lipid peroxidation, in breast fine-needle aspirate samples of 22 patients with breast cancer, at different clinical stages, in respect to 13 controls. The multivariate analysis show that M₁dG adduct was higher in cases than in controls (Mean Ratio (MR) == 5.26, 95% CI == 3.16--8.77). Increased M₁dG was observed in women with a tumour grade 3 and a pathological diameter 2 (MR == 7.61, 95% CI == 3.91--14.80 and MR == 5.75, 95% CI == 3.13--10.59, respectively). A trend with increasing tumour grade and pathological diameter was present (MR == 1.98, 95% CI == 1.57--2.50 and MR == 2.44, 95% CI == 1.71--3.48, respectively). Not significant effects of age and smoking habit were found (MR == 1.58, 95% CI == 0.92--2.72 and MR == 1.68, 95% CI 0.88--3.20, respectively). An increment over the background frequency of M₁dG can contribute to breast cancer development. Increasing severity of breast tumour can influence DNA damage level. [ABSTRACT FROM AUTHOR]